| Literature DB >> 32253245 |
Sathi Babu Chodisetti1, Adam J Fike1, Phillip P Domeier1, Stephanie L Schell1, Taryn E Mockus1, Nicholas M Choi1, Chelsea Corradetti2, Baidong Hou3, Hannah M Atkins4, Roberto Caricchio2, Thomas Decker5, Aron E Lukacher1, Nancy Olsen6, Ziaur S M Rahman7.
Abstract
Although STAT1 tyrosine-701 phosphorylation (designated STAT1-pY701) is indispensable for STAT1 function, the requirement for STAT1 serine-727 phosphorylation (designated STAT1-pS727) during systemic autoimmune and antipathogen responses remains unclear. Using autoimmune-prone B6.Sle1b mice expressing a STAT1-S727A mutant in which serine is replaced by alanine, we report in this study that STAT1-pS727 promotes autoimmune Ab-forming cell (AFC) and germinal center (GC) responses, driving autoantibody production and systemic lupus erythematosus (SLE) development. In contrast, STAT1-pS727 is not required for GC, T follicular helper cell (Tfh), and Ab responses to various foreign Ags, including pathogens. STAT1-pS727 is also not required for gut microbiota and dietary Ag-driven GC and Tfh responses in B6.Sle1b mice. By generating B cell-specific bone marrow chimeras, we demonstrate that STAT1-pS727 plays an important B cell-intrinsic role in promoting autoimmune AFC, GC, and Tfh responses, leading to SLE-associated autoantibody production. Our analysis of the TLR7-accelerated B6.Sle1b.Yaa SLE disease model expressing a STAT1-S727A mutant reveals STAT1-pS727-mediated regulation of autoimmune AFC and GC responses and lupus nephritis development. Together, we identify previously unrecognized differential regulation of systemic autoimmune and antipathogen responses by STAT1-pS727. Our data implicate STAT1-pS727 as a therapeutic target for SLE without overtly affecting STAT1-mediated protection against pathogenic infections.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32253245 PMCID: PMC9305983 DOI: 10.4049/jimmunol.2000170
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.426